A61P 25 - Drugs for disorders of the nervous system

Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
11/2004
11/18/2004	US20040229893 Substituted benzothiazole amide derivatives
11/18/2004	US20040229887 Novel imidazopyrimidinyl and imidazopyri dinyl derivatives
11/18/2004	US20040229883 Phenylcycloalkylmethylamino and phenylalkenylamino derivatives, including 1-phenyl-2-aminomethylcyclopropanes; therapy of metabolic, feeding, and sexual disorders including obesity
11/18/2004	US20040229882 dipeptide or tripeptide MC-1R and MC-4R agonists
11/18/2004	US20040229879 CRF receptor antagonists and methods relating thereto
11/18/2004	US20040229875 Administering compounds such as 4-(2-Amino-5-phenyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid dimethylamide for therapy of transplant rejection, melanoma, or a cancer selected from colon, breast, lung, kidney, ovary, pancreas, CNS, or cancer of the gastric tract
11/18/2004	US20040229874 5HT7 Antagonists and inverse agonists
11/18/2004	US20040229872 Substituted cyclohexane-1,4-diamine compounds with anti-diarrhea and peripheral analgesic activity
11/18/2004	US20040229871 Nitrogen compounds such as 2-(5-(4-Fluoro-benzyloxy)-1,3-dioxo -1,3-dihydro-isoindol-2-yl)-acetamide, used for prophylaxis of Alzheimer's disease; amine oxidase inhibitors
11/18/2004	US20040229870 Certain alkylene diamine-substituted heterocycles
11/18/2004	US20040229868 Heterocyclic compounds, methods for the preparation thereof, and uses thereof
11/18/2004	US20040229865 Cycloocta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
11/18/2004	US20040229862 Imidazo-benzothiazoles
11/18/2004	US20040229861 CGRP receptor antagonists
11/18/2004	US20040229859 Beta-amino acid compounds as integrin antagonists
11/18/2004	US20040229857 Neurotherapeutic composition and method
11/18/2004	US20040229845 Modified PSMA ligands and uses related thereto
11/18/2004	US20040229828 Administering a therapeutically effective amount of at least one pharmacologically acceptable oligonucleotide at least 10 nucleotides in length
11/18/2004	US20040229796 Copper-dependent non-traditional pro-inflammatory cytokine export and methods, compositions and kits relating thereto
11/18/2004	US20040229795 For oncological diseases and diseases accompanying neovascularization, immune complex-mediated and autoimmune diseases, viral infections, fibrotic and granulomatous diseases, allergic diseases, degenerative diseases of the nervous system and arteriosclerosis
11/18/2004	US20040229792 Peripheral nervous system specific sodium channels, DNA encoding therefor, crystallization, X-ray diffraction, computer molecular modeling, rational drug design, drug screening, and methods of making and using thereof
11/18/2004	US20040229217 Using glutamate transporter (BNPI)/(DNPI) proteins to identify agents which prevent and/or treat, vision, nervous system, autoimmune, inflammatory and viral disorders
11/18/2004	US20040228934 Compositions and methods of use for extracts of magnoliaceae plants
11/18/2004	US20040228923 Pulmonary delivery in treating disorders of the central nervous system
11/18/2004	US20040228914 Formulation
11/18/2004	US20040228906 Use of buprenorphine for the manufacture of a transdermal delivery device for the treatment of urinary incontinence, especially urge incontinence
11/18/2004	US20040228881 Compositions and methods for modulating neural sprouting
11/18/2004	US20040228879 Streptococcus pneumoniae polysaccharide is conjugated to protein or peptide, and RSV antigen with adjuvant which is stimmulator of (cytotoxic T) lymphocytes
11/18/2004	US20040228865 Prevention and treatment of amyloidogenic disease
11/18/2004	US20040228855 Method for treating symptoms of diabetes
11/18/2004	US20040228807 Condensation aerosol for delivery of a drug selected from the group consisting of zaleplon, zolpidem and zopiclone
11/18/2004	DE10318714A1 Wirkstoff-Kombination und Therapien zur Bekämpfung des Alkoholmissbrauchs Drug combination therapies to combat alcohol abuse
11/18/2004	CA2525195A1 Pyrazinones as crf1 receptor antagonists for the treatment of cns disorders
11/18/2004	CA2524904A1 Combination of a glycine/nmda antagonist and a tachykinin nk-1 receptor antagonist for use in the treatment of neurodegeneration
11/18/2004	CA2524894A1 Cyclic amine derivatives, processes for their preparation, and pharmaceutical compositions containing them
11/18/2004	CA2524625A1 Isoquinoline-3-carboxylic acid amides and pharmaceutical uses thereof
11/18/2004	CA2524611A1 A method for efficient transfer of human blastocyst-derived stem cells (hbs cells) from a feeder-supported to a feeder-free culture system
11/18/2004	CA2524593A1 Use of kynurenine-3-hydroxylase inhibitors for the preparation of medicaments for the treatment of l-dopa induced movement disorders, dyskinesias, drug addiction, pain and cataract
11/18/2004	CA2524571A1 Alzheimer's disease treatment method comprising a beta-amyloid peptide
11/18/2004	CA2524519A1 Compounds as crf1 receptor antagonists
11/18/2004	CA2524379A1 Methods for treating sinus headache
11/18/2004	CA2524342A1 Glutamate receptor antagonists as neuroprotectives
11/18/2004	CA2524324A1 Benzofuranyl-and benzothienyl-piperazinyl quinolines as serotonin reuptake inhibitors
11/18/2004	CA2524161A1 Pyridinyl acetonitriles
11/18/2004	CA2524019A1 Positive modulators of nicotinic acetylcholine receptors
11/18/2004	CA2523238A1 Amino-pyranoquinolines as serotonin reuptake inhibitors and 5-htia receptor agonists
11/18/2004	CA2523072A1 Pyrrolo (1,2-b) pyridazine compounds and their use as crf-1 receptor antagonists
11/18/2004	CA2521928A1 Freeze-dried preparation containing methylcobalamin and process for producing the same
11/18/2004	CA2521700A1 Piperidinyl- and piperazinyl-alkylcarbamate derivatives, preparation and therapeutic application thereof
11/17/2004	EP1477497A1 Humanized immunoglobulins and their production and use
11/17/2004	EP1477490A1 Pyrrolopyrimidine derivative
11/17/2004	EP1477489A1 Pyrrolopyrimidine derivatives
11/17/2004	EP1477482A1 Novel phenylalanine derivative
11/17/2004	EP1477479A1 Process for the preparation of the D-(-)-tartrate salt of 1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-YL)-1-propanol
11/17/2004	EP1477478A2 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses.
11/17/2004	EP1477472A1 Substituted phenylalkanoic acid derivative and use thereof
11/17/2004	EP1477183A1 Botulinum toxins for modulating cholinergic controlled secretions
11/17/2004	EP1477182A1 Novel analgesics
11/17/2004	EP1477175A1 Fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient
11/17/2004	EP1477169A1 Reactions of polymorphs of N-methyl-N-(3-(3-(2-thienylcarbonyl)-pyrazol-(1,5-alpha)-pyrimidin-7-yl)phenyl)acetamide
11/17/2004	EP1477168A1 Use of cabergoline in the treatment of restless leg syndrome
11/17/2004	EP1477166A1 The use of riluzol combined with excipients and additives for the treatment of disorders characterised by hyperproliferation of keratinocytes, in particular neurodermitis and psoriasis
11/17/2004	EP1477163A1 New film coating
11/17/2004	EP1477162A1 Controlled-release formulations coated with aqueous dispersions of ethylcellulose
11/17/2004	EP1476581A2 Recombinant bovine immunodeficiency virus based gene transfer system
11/17/2004	EP1476574A2 RNA INTERFERENCE MEDIATED INHIBITION OF TYPE 1 INSULIN-LIKE GROWTH FACTOR RECEPTOR (IGF-1R) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
11/17/2004	EP1476545A2 Aggrecanase molecules
11/17/2004	EP1476469A1 MONOCLONAL ANTIBODIES AGAINST EXTRACELLULAR LOOPS OF C5aR
11/17/2004	EP1476461A2 Immune-modulating peptide made of s. aureus enterotoxin b
11/17/2004	EP1476460A2 A nucleic acid encoding a g-protein-coupled receptor; and uses thereof
11/17/2004	EP1476458A2 Rna interference mediated inhibition of platelet derived growth factor (pdgf) and platelet derived growth factor receptor (pdgfr) gene expression using short interfering nucleic acid (sina)
11/17/2004	EP1476456A2 Compositions and methods for surrogate antibody modulation of an immune response and transport
11/17/2004	EP1476455A1 PARTIAL AND FULL AGONISTS OF A sb 1 /sb ADENOSINE RECEPTORS
11/17/2004	EP1476449A1 Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease
11/17/2004	EP1476448A2 Azabicyclic compounds for the treatment of disease
11/17/2004	EP1476444A1 Heterocyclic compounds possessing affinity at 5ht1-type receptors and use thereof in therapy
11/17/2004	EP1476438A1 Oxa- and thiadiazoles and their use as metalloproteinase inhibitors
11/17/2004	EP1476434A2 Pyridazine derivatives, use of the same as medicaments, pharmaceutical compositions and method for producing the same
11/17/2004	EP1476433A1 Novel tricycloimidazoline derivatives, method for production and use thereof as medicaments
11/17/2004	EP1476432A1 Therapeutic substituted indazole derivatives
11/17/2004	EP1476431A1 Tricyclic pyrazole derivatives for the treatment of inflammation
11/17/2004	EP1476428A1 Pyridyl sulfone derivatives as 5-ht6 receptor ligands
11/17/2004	EP1476200A2 Compositions and method for regulation of calcium-dependent signalling in brain
11/17/2004	EP1476195A2 Enhancement of the action of central and peripheral nervous system agents
11/17/2004	EP1476179A2 Methods of preventing or treating brain ischemia or brain injury
11/17/2004	EP1476171A2 Transportation of nucleic acid substances
11/17/2004	EP1476168A2 Use of co-releasing compounds for the manufacture of a medicament for the treatment of inflammatory diseases
11/17/2004	EP1476165A1 Substituted pyrimidinones and pyrimidinthiones
11/17/2004	EP1476162A1 Controlled synthesis of ziprasidone and compositions thereof
11/17/2004	EP1476161A1 Piperidine and piperazine derivatives possessing affinity at 5ht-1 type receptors
11/17/2004	EP1476159A2 Compositions and formulations of 9- nitrocamptothecin polymorphs and methods of use thereof
11/17/2004	EP1476158A1 Nicotinamide derivatives useful as pde4 inhibitors
11/17/2004	EP1476157A1 Nicotinamide derivatives useful as pde4 inhibitors
11/17/2004	EP1476151A1 1-arylsulfonyl-3-substitued indole and indoline derivates useful in the treatment of central nervous system disorders
11/17/2004	EP1476149A2 Substituted hydrazones as inhibitors of cyclooxygenase-2
11/17/2004	EP1476148A2 Partial dopamine-d2 receptor agonist plus serotonin and/oder noradrenaline inhibitor activity
11/17/2004	EP1476146A1 Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence
11/17/2004	EP1476141A2 Tamper-resistant transdermal opioid delivery devices
11/17/2004	EP1476031A1 Anxiolytic marcgraviaceae compositions containing betulinic acid, betulinic acid derivatives, and methods
11/17/2004	EP1476018A1 Immunostimulant compositions comprising aminoalkyl glucosaminide phosphates and saponins

1 ... 1029 1030 1031 1032 1033 1034 1035 1036 1037 1038 1039 1040 1041 1042 1043 1044 1045 1046 1047 1048 1049 ... 1833